2023 Presentation Dr Berry

Current sort has key articles at the top. Click on "Article Date" to sort by date, click on specific "tag" to view all articles in that category.

Title
Association of Mental Health Burden With Prenatal Cannabis Exposure From Childhood to Early Adolescence: Longitudinal Findings From the Adolescent Brain Cognitive Development (ABCD) Study
12/01/2022

Conclusions and relevance: This study suggests that prenatal cannabis exposure and its correlated factors are associated with greater risk for psychopathology during middle childhood. Cannabis use during pregnancy should be discouraged.     


prenatal, Pregnancy, mental health, study, Research, 2023 Presentation Dr Berry
Sperm DNA methylation alterations from cannabis extract exposure are evident in offspring
11/20/2022

Conclusions: This is the first characterization of the effect of cannabis exposure on the entirety of the rat sperm methylome. We identified CE-associated methylation changes across the sperm methylome, some of which persisted despite a "washout" period. Select methylation changes validated via bisulfite pyrosequencing, and genes associated with methylation changes were involved in early developmental processes. Preconception CE exposure is associated with detectable changes in offspring DNA methylation that are functionally related to changes in gene expression and cardiomegaly. These results support that paternal preconception exposure to cannabis can influence offspring outcomes.     


study, Research, rats, offspring, heredity, 2023 Presentation Dr Berry
Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain
11/16/2022

Findings  This meta-analysis of 20 studies of 1459 individuals found a significant pain reduction in response to placebo in cannabinoid randomized clinical trials. Media attention was proportionally high, with a strong positive bias, yet not associated with the clinical outcomes.
Meaning  These findings suggest that placebo has a significant association with pain reduction as seen in cannabinoid clinical trials, and the positive media attention may shape placebo responses in future trials.


Placebo, meta-analysis, JAMA, 2023 Presentation Dr Berry, study, Research
The Pharming of Cannabis: Have We Not Learned the Lesson from the Overuse of Opioids?
11/14/2022
opioid, 2023 Presentation Dr Berry
Marijuana Legalization and Opioid Deaths
02/16/2022

These results indicate that legal medical marijuana, particularly when available through retail dispensaries, is associated with higher opioid mortality. The results for recreational marijuana, while less reliable, also suggest that retail sales through dispensaries are associated with greater death rates relative to the counterfactual of no legal cannabis.


fatal, opioid, Fatalities, Medical, 2023 Presentation Dr Berry
How Weed Became the New OxyContin
01/16/2022

“I started seeing people with the worst psychosis symptoms that I have ever seen,” she told me. “And the worst delusions I have ever seen.”

These cases were even more acute than what she’d seen from psychotic patients on meth. Some of the delusions were accompanied by “severe violence.” But these patients were coming up positive only for cannabis.
Now, she believes she’s seeing the same thing all over again: the specious claims of medical benefits, the denial of adverse effects. “From Big Tobacco to Big Pharma to Big Marijuana—it’s the same people, and the same pattern.”

They’re made by putting pulverized marijuana into a tube and running butane, propane, ethanol, or carbon dioxide through it, which separates the THC from the rest of the plant. The end product is a wax that can be 70% to 80% THC. That wax can then be put in a vacuum oven and further concentrated into oils that are as much as 95% or even 99% THC. Known as “dabs,” this is what people put in their vape pens, and in states like California and Colorado it’s totally legal and easily available to children. “There are no caps on potency,” said Stack.
“There is research out there supporting the use of cannabis for some medical conditions,” said Stuyt, “But it’s all less than 10% THC. Nothing has been studied greater than 10%. But we have all this research showing that greater than 10% puts you at risk for psychosis, addiction, suicide, cannabis hyperemesis syndrome [constant, severe vomiting]—all these things that high-potency THC is doing.”


Stack, opioids, 2023 Presentation Dr Berry
Intensity of cannabis use: Findings from three online surveys
01/17/2020

           Findings: Respondents who reported using daily (i.e., 30 days in the past month) consumed almost twice as much per day of use on average as did those reporting less than daily. We find only modest increases in intensity among those using less than daily, but then a substantial increase (p< 0.001) for those who use daily. Most respondents report that on heavy or light use days their consumption differs from a typical day of use by a factor of 2 or more, but only about 25% of days were described as heavy or light. We estimate those using cannabis 21+ days a month account for 80% of consumption vs. 71% of the days of use.
Discussion: Daily cannabis users consume more intensively than others, including near-daily users. When possible, survey questions should move beyond the presence or absence of use and number of days used.     


Caulkins, 2023 Presentation Dr Berry
Statistics on Cannabis Users Skew Perceptions of Cannabis Use
01/17/2013

In summary, by sampling on use-days and amount used, we find that most of the consumption and, hence, most of the associated intoxication and flow of money into the black markets, comes from people who use frequently. Examining the number of users can be enlightening but does not fully capture the dynamics of cannabis usage. In order to understand market-related quantities like demand, and to better assess implications for crime, health, and productivity, researchers should analyze cannabis usage indicators like use-days and quantity consumed.


marijuana use, 2023 Presentation Dr Berry
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood
02/16/2010

Conclusions and Relevance  Although individual-level risk remains moderate to low and results from this study should be confirmed in future adequately powered prospective studies, the high prevalence of adolescents consuming cannabis generates a large number of young people who could develop depression and suicidality attributable to cannabis. This is an important public health problem and concern, which should be properly addressed by health care policy.


anxiety, depression, suicide, study, meta-analysis, Research, 2023 Presentation Dr Berry
Subscribe to 2023 Presentation Dr Berry